Syndesi sends for corporates in $21m series A

Belgium-based drug developer Syndesi Therapeutics has raised €17m ($20.8m) in a series A round co-led by Novo Seeds, a corporate venturing unit owned by pharmaceutical firm Novo.

Venture capital firm Fountain Healthcare Partners co-led the round, which included healthcare group Johnson & Johnson’s corporate venturing arm, Johnson & Johnson Innovation – JJDC, and V-Bio Ventures, an investment affiliate of research institute VIB.

Walloon government-owned investment firm Société régionale d’Investissement de Wallonie and Vives Louvain Technology Fund, the university venture fund…